Citation index
Steven P. Marso, MD
Research Medical Center, Kansas City, Missouri
Interventional cardiologist who led the LEADER cardiovascular outcomes trial for liraglutide and the SUSTAIN-6 trial for semaglutide, establishing cardiovascular benefit for GLP-1 receptor agonists.
Public profiles
Cited on Peptides Research Hub
- Semaglutide: research, pharmacology, and clinical evidence
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated cardiovascular risk reduction in people with obesity but without diabetes. This pillar covers mechanism, half-life, pharmacokinetics, pivotal trials, safety, and regulatory status.
- Semaglutide Safety Profile and Adverse Events
Semaglutide
This article summarizes adverse events from semaglutide's pivotal programs, the boxed warning for thyroid C-cell tumors, gastrointestinal event frequencies, pancreatitis, gallbladder disease, the retinopathy worsening signal from SUSTAIN-6, post-marketing suicidal ideation review, and considerations in pregnancy and lactation.
- Liraglutide: research, pharmacology, and clinical evidence
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza (diabetes) and Saxenda (weight management). This pillar covers structure, mechanism, half-life, the LEADER cardiovascular outcomes trial, the SCALE weight-management program, safety, and regulatory status across five major jurisdictions.